The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Rapid Response Innovation Awards, 2012CD163+ Macrophages as Tools for Neuroinflammatory Modulation in Parkinson’s Disease
Objective/Rationale:
Evidence in humans and in research models support a role for the immune system in the progression of Parkinson's disease. Our preliminary data suggest infiltration of peripheral... -
Neurotrophic Factors Challenge, 2012Effects of Recombinant CDNF Protein in Alpha-synuclein Model of Parkinson’s Disease in Pre-Clinical Models
Objective/Rationale:Neurotrophic factors have been explored as a novel treatment for Parkinson’s disease. Toxic effect of α-synucleinopathies, one of the hallmarks in PD pathophysiology, occurs in...
-
Research Grant, 2012The Transfer of Alpha-Synuclein: Mechanistic and Therapeutic Studies
Objective/Rationale:
This three-year collaborative project between three seasoned Parkinson’s disease (PD) investigators capitalizes on their extensive PD research experience and new understanding of... -
Rapid Response Innovation Awards, 2012Reversing Pre-existing Pathologies of Dopamine Neurons in an Alpha-synuclein Model
Objective/Rationale:
Alpha-synuclein has been identified to play the central role in Parkinson’s disease. Genome-wide association studies confirm alpha-synuclein as a risk factor for... -
Target Validation, 2012Small Molecule Ligand for TrkB/TrkC as a Novel Therapeutic for Parkinson's Disease
Objective/Rationale:
Ample evidence suggests that the neurotrophin (NT) receptors, TrkB and TrkC, would be particularly effective therapeutic targets for Parkinson’s disease (PD). Both... -
LRRK2 in the Immune System, 2012The Four Horsemen of G2019S
Objective/Rationale:
Using stem cell-derived neurons from individuals with Parkinson’s disease, we have found that dopaminergic neurons carrying the G2019S variant of LRRK2 are abnormally...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.